第一作者机构:[1]Univ Elect Sci & Technol China, Sichuan Clin Res Ctr Canc, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Affiliated Canc Hosp, Chengdu, Peoples R China
推荐引用方式(GB/T 7714):
Li J.,Li Q.,Lu S.,et al.Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S158-S158.
APA:
Li, J.,Li, Q.,Lu, S.,Jiang, L.,Li, L.&Xie, S. -H..(2023).Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA:
Li, J.,et al."Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S158-S158